MSU
CTOR

Mizuho Securities USA’s Citius Oncology CTOR Stock Holding History

Mizuho Securities USA’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-343,498
Closed -$3.86M – 639
2024
Q2 		$3.86M Buy
343,498
+12,498
+4% +$140K 0.09% 215
2024
Q1 		$3.64M Sell
331,000
-191,030
-37% -$2.1M 0.09% 55
2023
Q4 		$5.69M Buy
522,030
+32,048
+7% +$349K 0.13% 30
2023
Q3 		$5.22M Buy
489,982
+51,557
+12% +$550K 0.16% 50
2023
Q2 		$4.59M Buy
438,425
+135,675
+45% +$1.42M 0.15% 50
2023
Q1 		$3.07M Buy
302,750
+1
+0% +$10 0.18% 76
2022
Q4 		$3.04M Buy
+302,749
New +$3.07M 0.28% 65

Other funds holding CTOR

YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Mizuho Securities USA's CTOR Position: Q3 2024 in Review

Mizuho Securities USA sold out of Citius Oncology (CTOR) in Q3 2024, closing a stake of 343,498 shares — an estimated $3.86M sold.

Mizuho Securities USA first reported a position in CTOR in Q4 2022 and held it in 7 quarters. The position peaked at $5.69M in Q4 2023. 7 funds tracked by Wall St. Rank hold CTOR as of Q3 2024.

  • Mizuho Securities USA reported no remaining Citius Oncology position as of Q3 2024 after selling out during the quarter.
  • Mizuho Securities USA sold 343,498 Citius Oncology shares in Q3 2024, an estimated $3.86M.
  • Mizuho Securities USA first reported a position in Citius Oncology in Q4 2022 and held it in 7 quarters.
  • Mizuho Securities USA's Citius Oncology position peaked at $5.69M in Q4 2023.
  • 7 funds tracked by Wall St. Rank held Citius Oncology as of Q3 2024.

Based on Mizuho Securities USA's 13F filing for Q3 2024, filed 6 Nov 2024.